42 related articles for article (PubMed ID: 27567536)
1. Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma.
Raninga PV; He Y; Datta KK; Lu X; Maheshwari UR; Venkat P; Mayoh C; Gowda H; Kalimutho M; Hooper JD; Khanna KK
Mol Ther; 2023 Mar; 31(3):729-743. PubMed ID: 36560881
[TBL] [Abstract][Full Text] [Related]
2. Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma.
Van Loenhout J; Freire Boullosa L; Quatannens D; De Waele J; Merlin C; Lambrechts H; Lau HW; Hermans C; Lin A; Lardon F; Peeters M; Bogaerts A; Smits E; Deben C
Cells; 2021 Oct; 10(11):. PubMed ID: 34831159
[TBL] [Abstract][Full Text] [Related]
3. Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.
Onodera T; Momose I; Adachi H; Yamazaki Y; Sawa R; Ohba SI; Kawada M
J Biol Chem; 2020 Dec; 295(49):16678-16690. PubMed ID: 32978257
[TBL] [Abstract][Full Text] [Related]
4. D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H
Sciegienka SJ; Solst SR; Falls KC; Schoenfeld JD; Klinger AR; Ross NL; Rodman SN; Spitz DR; Fath MA
Free Radic Biol Med; 2017 Jul; 108():354-361. PubMed ID: 28389407
[TBL] [Abstract][Full Text] [Related]
5. The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity.
Prasad CB; Oo A; Liu Y; Qiu Z; Zhong Y; Li N; Singh D; Xin X; Cho YJ; Li Z; Zhang X; Yan C; Zheng Q; Wang QE; Guo D; Kim B; Zhang J
Nat Commun; 2024 May; 15(1):4667. PubMed ID: 38821952
[TBL] [Abstract][Full Text] [Related]
6. Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells.
Zheng P; Xia Y; Shen X; Lu H; Chen Y; Xu C; Qiu C; Zhang Y; Zou P; Cui R; Huang X
Int J Biol Sci; 2024; 20(1):249-264. PubMed ID: 38164168
[TBL] [Abstract][Full Text] [Related]
7. Gold Nanoclusters as Nanoantibiotic Auranofin Analogues.
Ndugire W; Raviranga NGH; Lao J; Ramström O; Yan M
Adv Healthc Mater; 2022 May; 11(9):e2101032. PubMed ID: 34350709
[TBL] [Abstract][Full Text] [Related]
8. Auranofin Resistance in
Ma CI; Tirtorahardjo JA; Jan S; Schweizer SS; Rosario SAC; Du Y; Zhang JJ; Morrissette NS; Andrade RM
Front Cell Infect Microbiol; 2021; 11():618994. PubMed ID: 33816332
[TBL] [Abstract][Full Text] [Related]
9. Selection and characterization of a human ovarian cancer cell line resistant to auranofin.
Landini I; Lapucci A; Pratesi A; Massai L; Napoli C; Perrone G; Pinzani P; Messori L; Mini E; Nobili S
Oncotarget; 2017 Nov; 8(56):96062-96078. PubMed ID: 29221187
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive chemical proteomics for target deconvolution of the redox active drug auranofin.
Saei AA; Gullberg H; Sabatier P; Beusch CM; Johansson K; Lundgren B; Arvidsson PI; Arnér ESJ; Zubarev RA
Redox Biol; 2020 May; 32():101491. PubMed ID: 32199331
[TBL] [Abstract][Full Text] [Related]
11. ROS and radiotherapy: more we care.
Sonveaux P
Oncotarget; 2017 May; 8(22):35482-35483. PubMed ID: 28415657
[No Abstract] [Full Text] [Related]
12. Comparison of the efficacy of the mouse hepatic and renal antioxidant systems against inflammation-induced oxidative stress.
Hukkamlı B; Dağdelen B; Sönmez Aydın F; Budak H
Cell Biochem Biophys; 2023 Jun; 81(2):299-311. PubMed ID: 36773183
[TBL] [Abstract][Full Text] [Related]
13. The Role of Biomimetic Hypoxia on Cancer Cell Behaviour in 3D Models: A Systematic Review.
Liu Y; Mohri Z; Alsheikh W; Cheema U
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809554
[TBL] [Abstract][Full Text] [Related]
14. Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells.
Haas B; Schütte L; Wos-Maganga M; Weickhardt S; Timmer M; Eckstein N
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30248944
[TBL] [Abstract][Full Text] [Related]
15. Selenoproteins in Tumorigenesis and Cancer Progression.
Short SP; Williams CS
Adv Cancer Res; 2017; 136():49-83. PubMed ID: 29054422
[TBL] [Abstract][Full Text] [Related]
16. Expression of the thioredoxin system in an in vivo-like cancer cell environment upon auranofin treatment.
Bhatia M; Lovitt CJ; Raninga PV; Avery VM; Di Trapani G; Tonissen KF
Eur J Cell Biol; 2016 Oct; 95(10):378-388. PubMed ID: 27567536
[TBL] [Abstract][Full Text] [Related]
17. Protection of CDC25 phosphatases against oxidative stress in breast cancer cells: evaluation of the implication of the thioredoxin system.
Beillerot A; Battaglia E; Bennasroune A; Bagrel D
Free Radic Res; 2012 May; 46(5):674-89. PubMed ID: 22360685
[TBL] [Abstract][Full Text] [Related]
18. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
19. The thioredoxin system in breast cancer cell invasion and migration.
Bhatia M; McGrath KL; Di Trapani G; Charoentong P; Shah F; King MM; Clarke FM; Tonissen KF
Redox Biol; 2016 Aug; 8():68-78. PubMed ID: 26760912
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
